Literature DB >> 26854930

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Nicolas Jacquelot, David P Enot, Caroline Flament, Nadège Vimond, Carolin Blattner, Jonathan M Pitt, Takahiro Yamazaki, María Paula Roberti, Romain Daillère, Marie Vétizou, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel.   

Abstract

Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and functional behavior of which is guided by chemokine or cytokine gradients. Here, we retrospectively analyzed the expression patterns of 9 homing receptors (CCR/CXCR) in naive and memory CD4+ and CD8+ T lymphocytes in 57 patients with metastatic melanoma (MMel) with various sites of metastases to evaluate whether T cell CCR/CXCR expression correlates with intratumoral accumulation, metastatic progression, and/or overall survival (OS). Homing receptor expression on lymphocytes strongly correlated with MMel dissemination. Loss of CCR6 or CXCR3, but not cutaneous lymphocyte antigen (CLA), on circulating T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 corresponded with lung involvement, and a rise in CCR10 or CD103 was associated with widespread dissemination. High frequencies of CD8+CCR9+ naive T cells correlated with prolonged OS, while neutralizing the CCR9/CCL25 axis in mice stimulated tumor progression. The expansion of CLA-expressing effector memory CD8+ T cells in response to a single administration of CTLA4 blockade predicted disease control at 3 months in 47 patients with MMel. Thus, specific CCR/CXCR expression patterns on circulating T lymphocytes may guide potential diagnostic and therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26854930      PMCID: PMC4767356          DOI: 10.1172/JCI80071

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

1.  Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Authors:  Wim H J Kruit; Heidi H van Ojik; Vincent G Brichard; Bernard Escudier; Thierry Dorval; Brigitte Dréno; Poulam Patel; Nicolas van Baren; Marie-Françoise Avril; Sophie Piperno; Amir Khammari; Marguerite Stas; Gerd Ritter; Bernard Lethé; Danièle Godelaine; Francis Brasseur; Yi Zhang; Pierre van der Bruggen; Thierry Boon; Alexander M M Eggermont; Marie Marchand
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

2.  CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin.

Authors:  Mingcan Xia; Shaomin Hu; Yaoyao Fu; Wensen Jin; Qiyi Yi; Yurika Matsui; Jie Yang; Mary Ann McDowell; Surojit Sarkar; Vandana Kalia; Na Xiong
Journal:  J Allergy Clin Immunol       Date:  2014-04-24       Impact factor: 10.793

3.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

Authors:  Michelle Hong; Anne-Laure Puaux; Caleb Huang; Laure Loumagne; Charlene Tow; Charles Mackay; Masashi Kato; Armelle Prévost-Blondel; Marie-Françoise Avril; Alessandra Nardin; Jean-Pierre Abastado
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

4.  CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.

Authors:  Praveen K Sharma; Rajesh Singh; Kristian R Novakovic; John W Eaton; William E Grizzle; Shailesh Singh
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

5.  CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

Authors:  C Monteagudo; J M Martin; E Jorda; A Llombart-Bosch
Journal:  J Clin Pathol       Date:  2006-03-07       Impact factor: 3.411

6.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

7.  Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.

Authors:  Eleanor Clancy-Thompson; Laura K King; Lenora D Nunnley; Irene M Mullins; Craig L Slingluff; David W Mullins
Journal:  Cancer Immunol Res       Date:  2013-11       Impact factor: 11.151

8.  Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.

Authors:  Huanhuan Joyce Chen; Jian Sun; Zhiliang Huang; Harry Hou; Myra Arcilla; Nikolai Rakhilin; Daniel J Joe; Jiahn Choi; Poornima Gadamsetty; Jeff Milsom; Govind Nandakumar; Randy Longman; Xi Kathy Zhou; Robert Edwards; Jonlin Chen; Kai Yuan Chen; Pengcheng Bu; Lihua Wang; Yitian Xu; Robert Munroe; Christian Abratte; Andrew D Miller; Zeynep H Gümüş; Michael Shuler; Nozomi Nishimura; Winfried Edelmann; Xiling Shen; Steven M Lipkin
Journal:  Nat Biotechnol       Date:  2015-05-25       Impact factor: 54.908

9.  Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.

Authors:  Patricia Pautier; Clara Locher; Caroline Robert; Alain Deroussent; Caroline Flament; Axel Le Cesne; Annie Rey; Ratislav Bahleda; Vincent Ribrag; Jean-Charles Soria; Gilles Vassal; Alexander Eggermont; Laurence Zitvogel; Nathalie Chaput; Angelo Paci
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

10.  Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells.

Authors:  Laura Rivino; Mara Messi; David Jarrossay; Antonio Lanzavecchia; Federica Sallusto; Jens Geginat
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

View more
  34 in total

1.  Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.

Authors:  Xiaofan Lu; Qianyuan Zhang; Yue Wang; Liya Zhang; Huiling Zhao; Chen Chen; Yaoyan Wang; Shengjie Liu; Tao Lu; Fei Wang; Fangrong Yan
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-11       Impact factor: 4.553

Review 2.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

3.  The Chemokine Receptor CXCR3 Promotes CD8+ T Cell Accumulation in Uninfected Salivary Glands but Is Not Necessary after Murine Cytomegalovirus Infection.

Authors:  Sofia Caldeira-Dantas; Thomas Furmanak; Corinne Smith; Michael Quinn; Leyla Y Teos; Adam Ertel; Drishya Kurup; Mayank Tandon; Ilias Alevizos; Christopher M Snyder
Journal:  J Immunol       Date:  2017-12-29       Impact factor: 5.422

4.  Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

Authors:  Chandra Sekhar Boddupalli; Noffar Bar; Krishna Kadaveru; Michael Krauthammer; Natopol Pornputtapong; Zifeng Mai; Stephan Ariyan; Deepak Narayan; Harriet Kluger; Yanhong Deng; Rakesh Verma; Rituparna Das; Antonella Bacchiocchi; Ruth Halaban; Mario Sznol; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  JCI Insight       Date:  2016-12-22

Review 5.  Anticancer effects of the microbiome and its products.

Authors:  Laurence Zitvogel; Romain Daillère; María Paula Roberti; Bertrand Routy; Guido Kroemer
Journal:  Nat Rev Microbiol       Date:  2017-05-22       Impact factor: 60.633

6.  Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

Authors:  Kilian Wistuba-Hamprecht; Alexander Martens; Florian Heubach; Emanuela Romano; Marnix Geukes Foppen; Jianda Yuan; Michael Postow; Phillip Wong; Domenico Mallardo; Bastian Schilling; Anna Maria Di Giacomo; Amir Khammari; Brigitte Dreno; Michele Maio; Dirk Schadendorf; Paolo A Ascierto; Jedd D Wolchok; Christian U Blank; Claus Garbe; Graham Pawelec; Benjamin Weide
Journal:  Eur J Cancer       Date:  2017-02-04       Impact factor: 9.162

Review 7.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

8.  CCL25 Signaling in the Tumor Microenvironment.

Authors:  Hina Mir; Shailesh Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  C-X-C motif receptor 3A enhances proliferation and invasiveness of colorectal cancer cells, and is mediated by C-X-C motif ligand 10.

Authors:  Eriko Nozaki; Takaaki Kobayashi; Hiroaki Ohnishi; Kouki Ohtsuka; Tadahiko Masaki; Takashi Watanabe; Masanori Sugiyama
Journal:  Oncol Lett       Date:  2020-01-21       Impact factor: 2.967

10.  An omega-3 polyunsaturated fatty acid derivative, 18-HEPE, protects against CXCR4-associated melanoma metastasis.

Authors:  Jieping Li; Chih-Yu Chen; Makoto Arita; Kuijin Kim; Xiangyong Li; Hongman Zhang; Jing X Kang
Journal:  Carcinogenesis       Date:  2018-12-13       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.